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Abstract 
Background: It has been estimated that chronic painful diabetic neuropathy (PDN) affects 1 
in 6 (16.2%) of all diabetic patients (Diabetes UK, 2010) yet the symptoms of PDN continue 
to present a huge challenge in its management both for physicians and patients.   
 
Objectives: To ascertain whether pregabalin is effective as a treatment for relieving pain in 
PDN and to identify which dose: 150/300/600 mg/d is most effective. 
 
Search methods: “Pregabalin” and “Painful Diabetic Neuropathy” were entered into Pubmed 
and Scirus. “Humans” and “randomised controlled trial” were entered as limiters. The search 
was completed using the Athens log in through the University of Plymouth on 28th February 
2011. 
 
Selection criteria: Randomised double-blind controlled trials, with patients diagnosed with 
Type 1 or Type 2 diabetes mellitus and a diagnosis of PDN for a duration of ≥1 year were 
selected. Studies which reported the effectiveness of taking dosages of pregabalin of 150 
mg per day (mg/d), 300 mg/d or 600 mg/d and a placebo for pain relief were used in this 
meta-analysis. Only completed studies were included. 
 
Data collection and analysis: The author used strict inclusion criteria to extract the data. 
Revman 5 was used to analyse the mean difference with 95% confidence intervals and fixed 
effects for pain relief when taking either pregabalin or placebo. 
 
Main results: The search yielded fourteen studies. Thirteen were available via the University 
of Plymouth subscription and one was requested via the inter-library loans service. Six 
studies including 1,628 participants were eligible as having the correct inclusion criteria and 
measuring the correct endpoints. Overall, pregabalin was more effective at reducing mean 
pain scores in comparison to the placebo with a total mean difference of -0.90 in favour of 
pregabalin. The dose 600 mg/d had a significant effect on pain relief in comparison to the 
placebo with a mean difference of -1.19 in favour of pregabalin. The dose 300 mg/d also had 
a significant effect on pain relief in comparison to the placebo with a mean difference of -
0.86 in favour of pregabalin. The dose 150 mg/d had a significant effect on pain relief in 
comparison to the placebo with a mean difference of -0.38 in favour of pregabalin. There 
was a significant difference in efficacy between 150 mg/d and 600 mg/d of pregabalin. There 
was no significant difference between 300 mg/d and 600 mg/d doses. There was also no 
significant difference between 150 mg/d and 300 mg/d doses of pregabalin. 
 
Conclusions: Pregabalin 150 mg/d, 300 mg/d and 600 mg/d effectively reduced pain in 
patients with PDN. 600 mg/d dose relieved pain most effectively and 150 mg/d was the least 
effective. 
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Background 
Description of painful diabetic neuropathy 
Currently, the prevalence of diabetes globally is 285 million and by 2030 this is 
estimated to rise to 438 million people (Diabetes UK, 2010). PDN can affect all 
people with diabetes irrelevant of the type of diabetes they are diagnosed with and is 
estimated to affect 1 in 6 (16.2%) of people with diabetes (Diabetes UK, 2010). It is 
most likely to develop in those people whose blood glucose is poorly controlled and 
those who have had a longer duration of diabetes (Pirat, 1977). Haemaglobin A1C 
(HbA1C) is a test that measures the amount of glucose bound to the haemaglobin in 
blood. This test is carried out approximately twice a year in diabetic patients (Walker 
and Rodgers, 2004). A good HbA1C result is 7% or below (Walker and Rodgers, 
2004). However, even with very good long-term glycaemic control (HbA1C < 7%) the 
incidence of PDN during a lifetime of a diabetic is 20% (Martin et al. 2006). This 
suggests that no matter how well blood glucose is managed, there will always be 
patients presenting with PDN. 
 
PDN can interfere with many aspects of life and it can severely negatively affect 
patients‟ daily functions. The symptoms of PDN are typically burning, aching and 
tingling pains (Huizinga and Peltier, 2007) which are sometimes described by 
patients as „electric-shock‟ and „stabbing‟ sensations. The pain is usually worst at 
night time (Boulton et al. 2005) and is usually excruciating (Aring et al. 2005). In an 
estimated 5-10% of diabetic patients, the symptoms of PDN significantly decrease 
quality of life (Rogers et al. 2004). There have been many advances in the 
understanding of the pathophysiology of PDN. However, there have been very few 
treatments that are aimed at interrupting these processes. Treatment has therefore 
focused on controlling blood glucose and painful symptoms. 
 
Aetiology of Painful Diabetic Neuropathy 
The mechanism by which PDN develops is not fully understood and research is still 
ongoing. PDN is thought to be the result of a number of different processes (Quan, 
2010). Unlike most cells in the body, neurons are insulin-independent. Glucose can 
pass from the outside of the cell to the inside without requiring insulin (Ryle and 
Donaghy, 1995). The glucose is used for energy as normal but excess glucose 
during hyperglycaemia will enter the polyol pathway and be converted by aldose 
reductase and sorbitol dehydrogenase enzymes into sorbitol (Quan, 2010). In people 
with hyperglycaemia, the excess levels of glucose in the blood rises and the affinity 
of the aldose reductase enzyme increases leading to higher levels of sorbitol to be 
produced.  The sorbitol cannot cross the cell membranes and so accumulates within 
the cell. The result of this is that osmotic stresses on the cells occur by excess water 
being drawn into the cell. This can damage the cells and even cause cell lysis. In 
addition, decreased membrane Na+/K+-ATPase activity, damage to axons and 
structural damage to neurons can lead to the abnormal generation of action 
potentials (Quan, 2010).  This means that the neurons are being inappropriately 
stimulated, leading to the chronic pain seen in PDN. The repair mechanisms of 
neurons are also affected in PDN.  Excess glucose reacts with nucleotides, proteins 
and lipids resulting in „advance glycation end products‟ (AGE). AGE is believed to 
interfere with the metabolism in cells and axonal transport (Ryle and Donaghy, 1995). 
Oxidative stress is also thought to contribute to PDN. In a hyperglycaemic state, the 
number of free radicals increases. These are believed to seriously affect several 
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mechanisms. These mechanisms include direct damage to blood vessels which 
leads to ischaemic nerves and AGE reaction facilitation (Quan, 2010). Tavakoli et al. 
(2008) emphasised that hyperglycaemia in the short-term may induce oxidative 
stress, which can consequently result in neuropathy, hence why HbA1C level may be 
more important than duration of diabetes as a risk factor for developing PDN.  
 
Description of pregabalin and how it may reduce pain 
Pregabalin belongs to the anticonvulsant class of drugs (British National Formulary, 
2011). It works by mimicking the gamma-aminobutyric acid (GABA) neurotransmitter 
in the central nervous system (Gajraj, 2007). It has been found to be inactive at 
GABAA and GABAB receptors and “is not converted metabolically to GABA” 
(Rosenstock et al. 2004). Also, it does not interfere with the uptake or degradation of 
GABA (Rosenstock et al. 2004). Pregabalin binds with high affinity to the alpha2-
delta subunit protein of voltage-gated calcium channels (Gee et al. 1996). By binding 
to the calcium channels, pregabalin reduces the inflow of calcium, which 
subsequently results in a decrease in the release of a number of different 
neurotransmitters (Fink et al. 2002) which include glutamate, substance P and 
noradrenaline (Dooley et al. 2000). When the neurotransmitters are not released, 
they cannot diffuse into the synaptic cleft and bind to the receptors on the 
postsynaptic cell. Therefore a nerve impulse is not generated (Rang et al. 2007). 
Hence the relief in pain. 
 
Why is this meta-analysis important? 
The management of PDN continues to be a huge challenge for doctors and their 
patients. An estimated 16.2% of people with diabetes will develop PDN (Diabetes UK, 
2010) making it a relatively common complication of diabetes. Furthermore, it is 
estimated that in 5-10% of diabetic patients, the painful symptoms of PDN 
significantly decrease their quality of life (Rogers et al. 2004). Treatment of PDN can 
often be challenging because it is difficult to select a pharmacological agent that is 
suitable from the many that are available. A „trial and error‟ method is often used until 
a suitable drug is found for the patient.  
 
In 2010, the National Institute for Clinical Excellence (NICE) published guidelines for 
the treatment of PDN which have suggested that pregabalin should be used as 
second-line treatment after amitriptyline or duloxetine has been tried. Rogers et al. 
(2004) supported this by stating that “pregabalin is more potent” meaning the 
therapeutic effect can be seen with low doses, which subsequently will result in 
fewer side effects.   
 
It is important that results from previous meta-analyses can be repeated with the 
addition of recent randomised controlled trials. This can then take into account new 
studies and determine whether results are consistent. This meta-analysis is therefore 
important to show whether pregabalin is effective as an analgesic in patients with 
PDN, particularly at the lower doses. 
 
Objectives 
1. To ascertain whether pregabalin is effective as a treatment for relieving pain 
in patients with PDN. 
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2. To identify which dose: 150/300/600 mg/d is most effective at relieving pain in 
patients with PDN. 
Methods 
Criteria for considering studies for this meta-analysis 
 
Identification of studies by electronic searches 
The studies were identified by searching Pubmed and Scirus using the key words 
“Pregabalin” and “Painful Diabetic Neuropathy”. 
The limits “humans” and “randomised controlled trial” were applied to the search. 
Required journals which were not subscribed to by the University of Plymouth were 
ordered through the inter-library loans service. 
 
Selection of studies 
The studies all had to satisfy strict inclusion criteria and if the study did not fulfil all of 
the criteria, it was excluded. 
 
Types of study 
This meta-analysis only used randomised double-blind controlled trials and the 
studies were only included if they used human subjects. 
 
Types of participants 
Males and females ≥ 18 years of age who had been diagnosed with diabetes 
mellitus and subsequently PDN. All participants had a HbA1C of ≥11%. 
 
Types of intervention 
Studies were included if they assessed the efficacy of pregabalin for doses of 150, 
300 or 600 mg/d in randomised controlled trials. The efficacy of pregabalin as an 
analgesic in PDN was compared against a placebo in each study. 
 
Outcomes measured 
The primary outcome measured was the analgesic effect from taking pregabalin. 
 
Data collection and analysis 
 
Data extraction and management 
The studies that matched the inclusion criteria were put into an inclusion table stating 
their main characteristics. Some of the studies investigated the effect of more than 
one dose of pregabalin. If the doses investigated were 150, 300 or 600 mg/d, they 
were used in the analysis. 
 
Measures of treatment effect 
The mean difference and standard error (SE) for mean pain scores of all doses of 
pregabalin in all six of the studies were entered into RevMan5. The standard error 
was calculated using the following equation (Gardner and Altman, 1986) for studies 
that did not state it in their results. 
 
SE = 
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Once all of the data was entered, RevMan calculated a weighted mean average so 
that it could show the effects of individual studies as a contribution to the total. Fixed 
effects models using inverse variance and 95% confidence intervals were used to 
calculate the mean difference between pregabalin and placebo trials for pain relief. 
The results of the comparisons were presented in forest plots. On a forest plot, there 
are blocks presented for each study. This shows the weight assigned to the study. 
The larger the area of the block, the greater weight the study has in the meta-
analysis. This would mean that the larger the block, the more the study would 
dominate the calculation of the pooled result. Either side of the block, there is a 
horizontal line. This represents the 95% confidence interval. Cochrane (2009) stated 
that “the confidence interval indicates where 95% of the results from the study would 
be expected to lie”. Heterogeneity was measured by RevMan by measuring I2. This 
enables the author to see if there is any variation between studies within the 
comparisons. 
 
Three more analyses were carried out using the same process outlined above. The 
first used a dose of 600 mg/d, the second used a dose of 300 mg/d and the third 
used a dose of 150 mg/d. An interval plot was then constructed using Excel to 
display the total mean difference and confidence intervals for each dose of 
pregabalin. 
 
To assess publication bias, a funnel plot was produced using RevMan for the overall 
effect of all pregabalin doses in relieving pain. A funnel plot was only produced for 
comparison one. The reason for this is that it is recommended by Cochrane (2009) 
that tests for funnel plot asymmetry are only to be used when there are at least 10 
studies included in the meta-analysis. When there are less than ten studies, “the 
powers of the tests are too low to determine chance from real asymmetry”.  
 
Results 
Description of studies 
 
Results of the search 
The search yielded 15 studies. Two of the studies were the same study but 
published in two different journals. So in total there were 14 studies. The 
characteristics of the studies were looked at in order to identify whether the study 
was to be included or excluded. Table 2 shows the characteristics of included 
studies and Table 3 shows the characteristics of excluded studies. Journals not 
subscribed to by the University of Plymouth were requested through the inter-library 
loans service. 
 
Included Studies 
Six studies which matched all the inclusion criteria were included in the meta-
analysis. All of the studies tested the efficacy of pregabalin to relieve pain in PDN 
and the main aims of each study can be seen in Table 1. The main characteristics of 
the included studies are outlined in Table 2. There were 11 individual trials for 
different doses of pregabalin within the six studies. A total of 1,628 participants, both 
male and female aged ≥18 years were used in the analysis. Five trials with 392 
participants contributed to the high dose comparison (600 mg/d), four trials with 490 
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participants contributed to the 300 mg/d dose and two trials with 178 participants 
contributed to the low dose (150 mg/d) comparison. 
 
Table 1: The main aims of the six studies used in this meta-analysis. 
 
Authors 
 
Year Title Aim 
Arezzo et al. 
 
2008 Efficacy and safety of 
pregabalin 600 mg/d for 
treating painful diabetic 
peripheral neuropathy: a 
double-blind placebo-
controlled trial. 
The main aim of this study was to 
evaluate the efficacy and safety of 
pregabalin 600 mg/d for PDN and 
to examine the impact of 
pregabalin on sensory and motor 
nerve conduction. 
Lesser et al.  
 
2004 Pregabalin relieves 
symptoms of painful diabetic 
neuropathy: a randomized 
controlled trial. 
The main aim of this study was to 
assess the efficacy of pregabalin 
75/300/600 mg/d for the 
symptomatic relief of PDN. 
Richter et al.  
 
2005 Relief of painful diabetic 
peripheral neuropathy with 
pregabalin: a randomized, 
placebo-controlled trial. 
The main aim was to evaluate the 
efficacy of pregabalin 150 or 600 
mg/d for the treatment of PDN. 
Rosenstock et 
al.  
 
 
2004 Pregabalin for the treatment 
of painful diabetic peripheral 
neuropathy: a double-blind, 
placebo-controlled trial. 
The main aim was to evaluate the 
effectiveness of pregabalin for the 
systematic treatment of PDN, in 
particular the relief of pain. 
 
Satoh et al. 
 
2011 Efficacy and safety of 
pregabalin for treating 
neuropathic pain associated 
with diabetic peripheral 
neuropathy: a 14 week, 
randomized, double-blind, 
placebo-controlled trial. 
The main aims of this study were to 
evaluate the efficacy, safety and 
pharmacokinetics of pregabalin as 
a treatment for PDN in Japanese 
patients. 
Tölle et al.  
 
2008 Pregabalin for relief of 
neuropathic pain associated 
with diabetic neuropathy: a 
randomized, double-blind 
study. 
The main aim of this study was to 
assess the efficacy and safety of 
pregabalin 150/300/600 mg/d to 
reduce pain in people with PDN. 
 
 
Table 2: Characteristics of included studies. Note: RCT = Randomised Controlled Trial. M = 
Male, F = Female. SD = Standard Deviation. 
 
Study 
 
Doubl
e-
Blind 
RCT 
M/F Mean 
Age 
(yrs) 
Mean 
durati
on of 
diabet
es 
Type of 
diabete
s 
Mean 
durati
on of 
PDN 
Place
bo 
Method and 
timing of 
pregabalin 
intake 
Efficacy 
and safety 
of 
pregabalin 
600 mg/d 
Doubl
e-
blind 
RCT 
M 
and 
F 
incl
ude
All 
subject
s ≥18. 
Mean 
age 
10 yrs Type 1 
and 
Type 2 
diabetes 
mellitus 
~5 yrs Place
bo not 
stated
. 
Pregabalin 600 
mg/d or 
placebo was 
administered 
as two divided 
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for treating 
painful 
diabetic 
peripheral 
neuropathy: 
a double-
blind 
placebo-
controlled 
trial. 
Arezzo et 
al. 2008 
d in 
stu
dy. 
167 
sub
ject
s in 
tota
l.  
not 
stated.  
with 
HbA1C≤1
1% 
doses. Daily 
dosage was 
escalated over 
a 1 week 
period 
beginning with 
a single dose of 
150 mg 
pregabalin on 
day 1 followed 
by two doses of 
150 mg 
pregabalin on 
days 2-6 and 
two doses of 
300 mg 
pregabalin on 
day 7 which 
were continued 
for 12 weeks. 
Pregabalin 
relieves 
symptoms 
of painful 
diabetic 
neuropathy: 
a 
randomized 
controlled 
trial. 
Lesser et 
al. 2004 
Doubl
e-
blind 
RCT 
 
 
 
 
 
 
 
 
202 
M 
135 
F 
59.9 
(10.5 
SD) 
Not 
stated. 
Type 1 
and 
Type 2 
diabetes 
mellitus 
with 
HbA1C≤1
1% 
(91% of 
subjects 
Type 2). 
1 to 5 
yrs. 
Mean 
durati
on of 
PDN 
for 
subjec
ts not 
stated
. 
Place
bo not 
stated
. 
Pregabalin or 
matching 
placebo 
capsules were 
administered 
orally, three 
times a day for 
a period of 5 
weeks. 
Relief of 
Painful 
Diabetic 
Peripheral 
Neuropathy 
with 
Pregabalin: 
A 
Randomize
d, Placebo-
Controlled 
Trial. 
Richter et 
al. 2005 
Doubl
e-
blind 
RCT 
 
 
 
 
 
 
 
149 
M 
97 
F 
57.1±1
0.3 for 
placeb
o. 
56.3±9
.4 for 
150 
mg/d 
patient
s. 
57.8±9
.5 for 
600 
mg/d 
patient
s. 
10.6±
8.3 yrs 
for 
placeb
o. 
8.2±9.
1 yrs 
for 
150 
mg/d 
patient
s. 
9.3±8.
8 yrs 
for 
600 
mg/d 
patient
s. 
Type 1 
and 
Type 2 
diabetes 
mellitus 
with 
HbA1C≤1
1% 
1 to 5 
yrs. 
Mean 
durati
on of 
PDN 
for 
subjec
ts not 
stated
. 
Place
bo not 
stated
. 
Pregabalin was 
provided as two 
differently sized 
capsules. 
One with small-
sized capsules 
containing 
25mg 
pregabalin or 
placebo and 
the other with 
large-sized 
capsules 
containing 100 
mg pregabalin 
or placebo. 
Patients took 2 
capsules from 
each bottle 3 
times daily. The 
treatment was 
given for 6 
weeks duration. 
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Pregabalin 
for the 
treatment 
of painful 
diabetic 
peripheral 
neuropathy: 
a double-
blind, 
placebo-
controlled 
trial. 
Rosenstoc
k et al. 
2004 
Doubl
e-
blind 
RCT 
164 
M 
128 
F 
59.7  
(11.4 
SD). 
9.3 yrs 
(10.3 
SD) 
Type 1 
and 
Type 2 
diabetes 
mellitus 
with 
HbA1C≤1
1% 
(87% of 
patients 
had 
Type 2). 
1 to 5 
yrs. 
Mean 
durati
on of 
PDN 
for 
subjec
ts not 
stated
. 
Lacto
se 
USP 
All medications 
were packaged 
in blinded 
fashion and 
administered 
orally. 
Capsules were 
supplied in 
bottles, and 
patients were 
instructed to 
take one 
capsule three 
times a day for 
8 weeks. 
Efficacy 
and safety 
of 
pregabalin 
for treating 
neuropathic 
pain 
associated 
with 
diabetic 
peripheral 
neuropathy: 
a 14 week, 
randomized
, double-
blind, 
placebo-
controlled 
trial. 
Satoh et 
al. 2011 
Doubl
e-
blind 
RCT 
240
M 
77F 
61.3 
(9.6 
SD) for 
placeb
o. 
61.3 
(10.3 
SD) for 
300 
mg/d 
subject
s. 
62.2 
(10.3 
SD) for 
600 
mg/d 
subject
s. 
Not 
stated. 
Type 1 
and 
Type 2 
diabetes 
mellitus.  
Not 
stated
. 
Place
bo not 
stated
. 
Patients took 
pregabalin 150 
or 300 mg or 
placebo twice 
daily during the 
12-week fixed-
dose treatment 
phase. A 1 
week titration 
phase was 
conducted 
previously to 
this whereby 
patients took 
pregabalin 75 
mg twice daily 
and was slowly 
increased until 
the target dose 
was reached. 
Pregabalin 
for relief of 
neuropathic 
pain 
associated 
with 
diabetic 
neuropathy: 
A 
randomized
, double-
blind study. 
Tölle et al. 
2008 
Doubl
e-
blind 
RCT 
219
M 
176
F 
58.61 
yrs 
(11.5 
SD) 
Not 
stated. 
Type 1 
and 
Type 2 
diabetes 
mellitus 
with 
HbA1C≤1
1% 
≥1 
year. 
Mean 
durati
on of 
PDN 
for 
subjec
ts not 
stated
. 
Place
bo not 
stated
. 
Placebo/150/30
0/600 mg/day 
pregabalin 
were all 
administered 
by twice daily 
dosing for 11 
weeks. 
 
Excluded Studies 
Eight studies were excluded because they did not match the inclusion criteria. The 
reasons for exclusion from the analysis are shown in Table 3. 
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Table 3: Characteristics of excluded studies 
Excluded study Reason for exclusion 
Bansal et al. 2009 
 
This study did not state the HbA1C level for the patients. 
Baron et al. 2009 
 
The study was not limited to pregabalin. It assessed a 
combination therapy. Also, it included postherpetic 
neuralgia patients. 
Baron et al. 2008 
 
This was an open-label, flexible-dose study. Patients were 
not limited to PDN. 
Freynhagen et al. 2006 
 
Assessed pregabalin for neuropathic pain in general and 
was not specific to PDN patients. 
Freynhagen et al. 2005 
 
Assessed pregabalin for neuropathic pain in general and 
was not specific to PDN patients. 
Hoffman et al. 2010 
 
This study didn‟t assess pregabalin. It assessed health 
status. 
Rodriguez et al. 2007 
 
This study was a cost-effective analysis looking at both 
PDN and postherpetic neuralgia patients. 
Zin et al. 2010 
 
This study included both PDN and postherpetic neuralgia 
patients. 
 
 
Effects of interventions 
 
Comparison 1: Overall effect of all doses of pregabalin as an analgesic. 
The forest plot for comparison 1 did show some variation in the results. The overall 
standardised mean difference in mean pain score calculated using the fixed effects 
model was -0.90 in favour of pregabalin (P < 0.00001) (Figure 1). There was 
moderate heterogeneity (I2 = 66%) (P = 0.0009). 
 
 
 
Figure 1: Forest plot of comparison one: All doses of Pregabalin versus Placebo, outcome: 
analgesic effect. All pregabalin doses showed a more significant analgesic effect compared 
to placebo. 
 
Study or Subgroup
a) Lesser et al. 2004
a) Richter et al. 2005
a) Satoh et al. 2011
a) Tolle et al. 2008
Arezzo et al. 2008
b) Lesser et al. 2004
b) Richter et al. 2005
b) Satoh et al. 2011
b) Tolle et al. 2008
c) Tolle et al. 2008
Rosenstock et al. 2004
Total (95% CI)
Heterogeneity: Chi² = 29.76, df = 10 (P = 0.0009); I² = 66%
Test for overall effect: Z = 10.87 (P < 0.00001)
Mean Difference
-1.45
-1.264
-0.74
-0.91
-1.28
-1.26
-0.44
-0.63
-0.1
-0.27
-1.47
SE
0.23
0.26
0.33
0.31
0.35
0.23
0.24
0.23
0.31
0.31
0.37
Weight
13.1%
10.2%
6.3%
7.2%
5.6%
13.1%
12.0%
13.1%
7.2%
7.2%
5.0%
100.0%
IV, Fixed, 95% CI
-1.45 [-1.90, -1.00]
-1.26 [-1.77, -0.75]
-0.74 [-1.39, -0.09]
-0.91 [-1.52, -0.30]
-1.28 [-1.97, -0.59]
-1.26 [-1.71, -0.81]
-0.44 [-0.91, 0.03]
-0.63 [-1.08, -0.18]
-0.10 [-0.71, 0.51]
-0.27 [-0.88, 0.34]
-1.47 [-2.20, -0.74]
-0.90 [-1.07, -0.74]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours Pregabalin Favours Placebo
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Comparison 2: Efficacy of 600 mg/d of pregabalin as an analgesic for PDN. 
The forest plot showed the results of studies for mean difference and 95% 
confidence intervals were not significantly different. This shows that all of the studies 
showed a positive effect for pregabalin as an analgesic. 
  
The overall standardised mean difference in mean pain score calculated using the 
fixed effects model was -1.19 in favour of pregabalin (P < 0.00001) (Figure 2). There 
was very low heterogeneity (I2 = 2%) (P = 0.39). 
 
 
 
Figure 2: Forest plot of comparison two: 600 mg/day of Pregabalin versus Placebo, 
outcome: analgesic effect. 600 mg/day pregabalin showed a more significant analgesic 
effect compared to placebo. 
 
 
Comparison 3: Efficacy of 300 mg/d of pregabalin as an analgesic for PDN. 
The forest plot showed that the 300 mg/d trials differed in their efficacy.  
The overall standardised mean difference in mean pain score calculated using the 
fixed effects model was -0.86 in favour of pregabalin (P < 0.00001) (Figure 3). There 
was high heterogeneity (I2 = 76%) (P = 0.005). 
 
 
 
Figure 3: Forest plot of comparison three: 300 mg/day of Pregabalin versus Placebo, 
outcome: analgesic effect. 300 mg/day pregabalin showed a more significant analgesic 
effect compared to placebo 
 
 
 
 
 
Study or Subgroup
a) Lesser et al. 2004
a) Richter et al. 2005
a) Satoh et al. 2011
a) Tolle et al. 2008
Arezzo et al. 2008
Total (95% CI)
Heterogeneity: Chi² = 4.10, df = 4 (P = 0.39); I² = 2%
Test for overall effect: Z = 9.29 (P < 0.00001)
Mean Difference
-1.45
-1.264
-0.74
-0.91
-1.28
SE
0.23
0.26
0.33
0.31
0.35
Weight
30.8%
24.1%
14.9%
16.9%
13.3%
100.0%
IV, Fixed, 95% CI
-1.45 [-1.90, -1.00]
-1.26 [-1.77, -0.75]
-0.74 [-1.39, -0.09]
-0.91 [-1.52, -0.30]
-1.28 [-1.97, -0.59]
-1.19 [-1.44, -0.94]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours Pregabalin Favours Placebo
Study or Subgroup
a) Lesser et al. 2004
a) Satoh et al. 2011
a) Tolle et al. 2008
Rosenstock et al. 2004
Total (95% CI)
Heterogeneity: Chi² = 12.75, df = 3 (P = 0.005); I² = 76%
Test for overall effect: Z = 6.38 (P < 0.00001)
Mean Difference
-1.26
-0.63
-0.1
-1.47
SE
0.23
0.23
0.31
0.37
Weight
34.0%
34.0%
18.7%
13.2%
100.0%
IV, Fixed, 95% CI
-1.26 [-1.71, -0.81]
-0.63 [-1.08, -0.18]
-0.10 [-0.71, 0.51]
-1.47 [-2.20, -0.74]
-0.86 [-1.12, -0.59]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours Pregabalin Favours Placebo
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Comparison 4: Efficacy of 150 mg/d of pregabalin as an analgesic for PDN. 
The forest plot showed the results of studies for mean difference and 95% 
confidence intervals were not significantly different. This shows that all of the studies 
showed a positive effect for pregabalin as an analgesic. 
 
The overall standardised mean difference in mean pain score calculated using the 
fixed effects model was -0.38 in favour of pregabalin (P = 0.05) (Figure 4). There 
was no heterogeneity (I2 = 0%) (P = 0.66). 
 
 
 
Figure 4: Forest plot of comparison four: 150 mg/day of Pregabalin versus Placebo, 
outcome: analgesic effect. 150 mg/day pregabalin showed a more significant analgesic 
effect compared to placebo. 
 
Comparison 5: Comparing the mean differences for the three pregabalin doses 600 
mg/d, 300 mg/d and 150 mg/d. 
The interval plot showed that the 150 mg/d and 600 mg/d doses of pregabalin were 
significantly different as the 95% confidence intervals do not overlap. 300 mg/d and 
600 mg/d pregabalin doses show that they are not significantly different because the 
confidence intervals overlap. The 150 mg/d and 300 mg/d doses also show that they 
are not significantly different because the confidence intervals overlap (Figure 5). 
 
 
 
Figure 5: An interval plot for doses 600 mg/d, 300 mg/d and 150 mg/d. The 150 mg/d and 
600 mg/d doses show they are significantly different because the confidence intervals do not 
overlap. There are no significant differences between 150 mg/d and 300 mg/d. There are 
also no significant differences between 300 mg/d and 600 mg/d. 
 
Study or Subgroup
a) Richter et al. 2005
a) Tolle et al. 2008
Total (95% CI)
Heterogeneity: Chi² = 0.19, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 1.98 (P = 0.05)
Mean Difference
-0.44
-0.27
SE
0.24
0.31
Weight
62.5%
37.5%
100.0%
IV, Fixed, 95% CI
-0.44 [-0.91, 0.03]
-0.27 [-0.88, 0.34]
-0.38 [-0.75, -0.00]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours Pregabalin Favours Placebo
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The data for comparison one was plotted using a funnel plot (Figure 6). This was 
symmetrical and so did not show publication bias. 
 
 
 
Figure 6: Funnel plot of comparison one: All doses of Pregabalin versus Placebo, outcome: 
analgesic effect. 
 
 
Discussion 
 
Overall completeness and applicability of evidence 
After looking at the results, a conclusion can be made that all pregabalin doses 
significantly relieve pain in patients with PDN. These results are supported by Hurley 
et al. (2008) who conducted a meta-analysis of randomised controlled trials involving 
728 participants and doses of pregabalin between 75-600 mg/d. A weighted mean 
difference of 1.15 was seen between pregabalin and placebo for all dosages and it 
was shown that pregabalin significantly reduces pain scores. Additional supportive 
research comes from Sharma et al. (2000) who found that pregabalin at a dose of 
300 mg/d or above showed significant reduction in pain from PDN which is in line 
with the results found in this meta-analysis. Furthermore, a meta-analysis conducted 
by Semel et al. (2010) involving 2516 patients, studied 150-600 mg/d pregabalin for 
neuropathic pain and found results in line with this analysis. However, unlike this 
study, Semel et al (2010) found no significant difference between baseline and 
endpoint mean pain score for the 150 mg/d dose. Only two studies were included in 
this meta-analysis for the 150 mg/d dose. When looking at comparison 4 for 150 
mg/d, the lower value for the 95% confidence interval was -0.00 (Figure 4). If more 
studies had have been included, this value may have been lower and results similar 
to Semel et al. (2010) may have been found. However, Semel et al. (2010) included 
both post-herpetic neuralgia and PDN patients in their meta-analysis. It therefore is 
not specific to PDN. A strength of this study is that it is specific to PDN patients only 
therefore the results from this study may be more applicable. 
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In this meta-analysis, a dose- response relationship of pregabalin was seen for all 
three doses. However, there was only a significant difference in mean difference of 
mean pain scores (with 95% confidence intervals) between 150 mg/d and 600 mg/d 
doses. There was not a significant difference between 300 mg/d and 600 mg/d and 
there was also no significant difference between 150 mg/d and 300 mg/d pregabalin 
in reducing the mean pain scores. The results of this meta-analysis therefore support 
the use of 150 mg/d pregabalin initially for the treatment of patients with PDN with 
the aim of achieving pain relief at the lowest dose possible. However, if the patient 
does not feel that this dose gives sufficient pain relief, titrating the dose upwards 
would be recommended to either 300 mg/d or 600 mg/d to whichever suits the 
patient best. This is supported by the national institute for clinical excellence (NICE) 
who state that 150 mg/d should be the starting dose and that it should be titrated 
upwards to achieve the “person‟s maximum tolerated dose up to a maximum dose of 
600 mg/d” (NICE, 2010). By taking the approach of starting at the lower dose, it will 
prove to be more cost effective. 150 mg/d and 300 mg/d capsules of pregabalin cost 
£64.40 for a packet of 56-capsules, whereas 600 mg/d capsules cost £128.80 
(British National Formulary, 2011). 
 
The original objectives were met in this meta-analysis as conclusions were able to 
be drawn and show that pregabalin is effective as an analgesic in patients with PDN. 
The second objective was also met, as all three doses: 150mg/d, 300 mg/d and 600 
mg/d were identified as being suitable for use in treating PDN. 
 
Quality of the evidence variation 
Cochrane (2009) stated that a systematic review is likely to contain heterogeneity 
due to the diversity in scientific method (as well as other factors) as different studies 
are being combined in one analysis. Therefore, to a certain extent, heterogeneity is 
to be expected. In this meta-analysis, the I2 test was used to test for heterogeneity. 
The I2 expresses the amount of heterogeneity as a percentage. Low heterogeneity is 
25%, moderate describes a heterogeneity of 50% and 75% is described as high 
(Higgins et al. 2003).  
The heterogeneity in this meta-analysis varied greatly between comparisons, ranging 
from zero to high heterogeneity (comparison 1 = 66%, comparison 2 = 2%, 
comparison 3 = 76% and comparison 4 = 0%). A reason for the 0% heterogeneity in 
comparison 4 could be that only two studies were included in this comparison. If 
more studies for 150 mg/d pregabalin would have been included, a larger variation in 
the data may have been seen. 
 
One reason heterogeneity could have been increased in comparisons 1 and 3 is due 
to patients in the studies included not acting as their own controls. A separate group 
of patients were selected to take the placebo. This may have implications on the 
validity of this meta-analysis. There are a number of varying factors associated with 
individuals which can influence the drug responses in patients. These include 
genetic variation, other drugs a person may be taking, remembering to take the 
pregabalin, along with others. A more scientifically valid study would have been to 
only include randomised controlled, double-blind crossover studies in this meta-
analysis. This would have ensured that the patients would have acted as their own 
controls. However, cross-over studies are not without disadvantages. Also, unless 
the patients are made to take the drug in front of the experimenter (which is 
The Plymouth Student Scientist, 2012, 5, (1), 61-78 
 
[74] 
 
unrealistic and not practical), it is never going to be possible to be one hundred 
percent sure that patients have remembered to take the drug.  
 
The heterogeneity seen in comparison 1 may be due to all of the doses being 
included in this comparison. There was a significant difference in the mean 
differences between 150 mg/d and 600 mg/d (Figure 5) which is displayed by the 
moderate variance seen. Glasziou and Sanders (2002) suggested that heterogeneity 
may be due to two main reasons. The first reason is that „study design features‟ can 
vary e.g., duration of follow-up. Secondly, the heterogeneity may be due to „real 
variation‟. This includes factors that may affect the treatment effect e.g. age, gender 
and intervention factors such as dose, timing and duration of treatment (Glasziou 
and Sanders, 2002). The studies included in this meta-analysis differed in the 
„duration of treatment‟. Duration of treatment ranged between 5 and 12 weeks. This 
factor could have caused heterogeneity.  
 
A limitation of this analysis is that the studies that were included only tested 
pregabalin treatment for 12 weeks or less. Therefore it is beyond the scope of this 
analysis to predict the long-term effectiveness or safety of pregabalin as a treatment 
for PDN for more than 12 weeks duration. Long-term use of the drug may cause 
patients to become resistant to the drug or develop side-effects. Furthermore, the 
tolerability of pregabalin over a long term needs to be tested. Long-term trials on the 
use of pregabalin for diabetic neuropathy are lacking and future studies should focus 
on assessing the long-term use of pregabalin in PDN patients. However, despite this, 
pregabalin has been shown to be tolerable and safe in a long-term 18 month study 
by Uthman et al. (2010) who studied the use of pregabalin in epileptic patients and 
confirmed it to be safe, effective and generally well tolerated in long-term use. 
Furthermore, pregabalin has been identified as being a drug “free from drug-drug 
interactions”. It therefore provides a suitable treatment option for elderly patients in 
particular who may be more at risk of possible drug-drug interactions due to their 
polypharmacy. 
 
Each of the six studies included in this meta-analysis required patients to record their 
pain scores using the Likert pain scale of 1-10 in a diary. This method of measuring 
treatment effect is subjective. However, although this is a subjective and non-
scientific method, it should be emphasised that pain is a subjective experience which 
differs from patient to patient. Therefore, there is no objective way of measuring pain. 
 
Publication bias 
It is important to take into account publication bias. The results of the studies 
included in this meta-analysis showed only positive results. Because of this, there 
was a risk that there may have been publication bias in the studies of pregabalin 
treatment for PDN. When publication bias is present in a meta-analysis, it suggests 
that the published studies may not be a true representation of all the valid studies 
that have been carried out. The publication bias can have a knock-on effect for meta-
analyses and systematic reviews, leading to incorrect conclusions to be made. This 
can ultimately result in healthcare professionals making inaccurate choices about 
patient treatment (Chalmers, 1990). A funnel plot was constructed for comparison 
one. The funnel plot was symmetrical (Figure 6) demonstrating that publication bias 
was not present in this meta-analysis and showing that the positive results reported 
in the studies were due to pregabalin being an effective analgesic for PDN. 
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Conclusions 
In conclusion, the analgesic effect of pregabalin in patients with PDN was reported 
for all three 150mg/d, 300 mg/d and 600 mg/d doses. A dose-response relationship 
was seen for all three dosages. However, there is a significant difference between 
150 mg/d and 600 mg/d pregabalin. This study supports the use of 150 mg/d 
pregabalin for treating PDN. If 150 mg/d is unsuccessful, the dose should be titrated 
upwards to 300 mg/d or 600 mg/d to achieve analgesia. 
 
Acknowledgements 
Special thanks to Dr Stephen Thompson at the School of Biomedical & Biological 
Sciences at the University of Plymouth for providing guidance on this report. 
 
References 
References to studies included in this meta-analysis 
Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L. (2008). Efficacy and safety of 
pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-
blind placebo-controlled trial. BMC Neurology. 16 (8), p33. 
Lesser H, Sharma U, LaMoreaux L, Poole RM. (2004). Pregabalin relieves 
symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 
63 (11), p2104-2110. 
Richter RW, Portenoy R, Sharma U, LaMoreaux L, Bockbrader H, Knapp LE. (2005). 
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, 
placebo-controlled trial. Journal of Pain. 6 (4), p253-260. 
Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. (2004). Pregabalin for the 
treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-
controlled trial. Pain. 110 (3), p628-638. 
Satoh J, Yagihashit S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, Shoji S. (2011). 
Efficacy and safety of pregabalin for treating neuropathic pain associated with 
diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-
controlled trial. Diabetic medicine. 28, p109-116. 
 
Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. (2008). Pregabalin 
for relief of neuropathic pain associated with diabetic neuropathy: a randomized 
double-blind study. European Journal of Pain. 12 (2), p203-213. 
 
References to studies excluded from this meta-analysis 
Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. (2009). Amitriptyline versus 
pregabalin in painful diabetic neuropathy: a randomized double blind clinical 
trial. Diabetic medicine. 26 (10), p1019-26. 
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. (2009). Efficacy 
and safety of combination therapy with 5% lidocaine medicated plaster and 
pregabalin in postherpetic neuralgia and diabetic neuropathy. Clinical drug 
investigation. 29 (4), p231-41. 
The Plymouth Student Scientist, 2012, 5, (1), 61-78 
 
[76] 
 
Baron R, Brunnmüller U, Brasser M, May M, Binder A. (2008). Efficacy and safety of 
pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: 
Open-label, non-comparative, flexible-dose study. European Journal of Pain. 12 (7), 
p850-858. 
Freynhagen R, Busche P, Konrad C, Balkenohl M. (2006). Effectiveness and time to 
onset of pregabalin in patients with neuropathic pain. Schmerz. 20 (4), p285-8, 290-2. 
Freynhagen R, Stojek K, Griesing T, Whalen E, Balkenohl M. (2005). Efficacy of 
pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, 
multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain. 115 (3), 
p254-263. 
Hoffman DL, Sadosky A, Dukes EM, Alvir J. (2010). How do changes in pain severity 
levels correspond to changes in health status and function in patients with painful 
diabetic peripheral neuropathy?. Pain. 149 (2), p194-201. 
Rodriguez MJ, Diaz S, Vera-Llonch M, Dukes E, Rejas J. (2007). Cost-effectiveness 
analysis of pregabalin versus gabapentin in the management of neuropathic pain 
due to diabetic polyneuropathy or postherpetic neuralgia. Current medical research 
and opinion. 23 (10), p2585-96. 
Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. (2010). A 
randomized, controlled trial of oxycodone versus placebo in patients with 
postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. The 
Journal of Pain. 11 (5), p462-7. 
Additional studies 
Aring AM, Jones DE, Falko JM. (2005). Evaluation and prevention of diabetic 
neuropathy. American Family Physician. 71, p2123-2128. 
 
British National Formulary. (2011). Pregabalin. Available: 
http://bnf.org/bnf/bnf/current/129078.htm#_129078. Last accessed 7th March 2011. 
 
Boulton AJM, Vinik A, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser 
RE, Sosenko JM, Ziegler D. (2005). Diabetic neuropathies: a statement by the 
American Diabetes Association. Diabetes Care. 28 , p956-962. 
 
Chalmers I. (1990). Underreporting research is scientific misconduct .The Journal of 
the American Medical Association. 263 (10), p1405-1408. 
Cochrane. (2009). Cochrane Handbook for Systematic reviews of 
Interventions. Available: http://www.cochrane-handbook.org/. Last accessed 8th 
March 2011. 
Diabetes UK. (2010). Diabetes in the UK 2010: Key Statistics on Diabetes. Available: 
Last accessed 21st Jan 2011. 
Dooley DJ, Donovan CM, Pugsley TA. (2000). Stimulus-dependent modulation of 
[3H]-norepinephrine release from rat neocortical slices by gabapentin and 
pregabalin. Journal of Pharmacology and Experimental Therapeutics. 295, p1086-
1093. 
The Plymouth Student Scientist, 2012, 5, (1), 61-78 
 
[77] 
 
Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. 
(2002). Inhibition of neuronal calcium influx by gabapentin and pregabalin in the 
human neocortex.. Neuropharmacology. 42, p229-236. 
Gardner MJ, Altman DG. (1986). Confidence intervals rather than P values: 
estimation rather than hypothesis testing. British Journal of Medicine. 292, p746-750. 
Gajraj NM. (2007). Pregabalin: its pharmacology and use in pain 
management. Anesthesia and Analgesia. 105, p1805-1815. 
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. (1996). 
The novel anticonvulsant drug, gabapentin (Neurotin), binds to the alpha2-delta 
subunit of a calcium channel. Journal of Biological chemistry. 271, p5768-5776. 
Glasziou PP, Sanders SL. (2002). Investigating causes of heterogeneity in 
systematic reviews. Statistics in Medicine. 21, p1503-1511.  
Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003). Measuring inconsistency 
in meta-analyses. British Medical Journal. 327, p557-560. 
Huizinga M, Peltier A. (2007). Painful Diabetic Neuropathy: A Management-Centred 
Review. Clinical Diabetes. 25 (1), p6-15. 
Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. (2008). Pregabalin as a 
treatment for painful diabetic peripheral neuropathy: a meta-analysis. Regional 
anesthesia and pain medicine. 33 (5), p389-94. 
Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, 
Feldman EL. (2006). Neuropathy among the diabetes control and complications trial 
cohort 8 years after trial completion. Diabetes Care. 29, p340-344. 
NICE (2010). The pharmacological management of neuropathic pain in adults in 
non-specialist settings. NICE Clinical guideline 96: Neuropathic Pain. p15-16. 
Pirat J. (1977). Diabetes mellitus and its degenerative complications: a prospective 
study of 4,400 patients observed between 1947 and 1973 (author's 
translation). Diabetes metabolism . 3, p245-256. 
Quan D. (2010). Diabetic neuropathy. Available: 
http://emedicine.medscape.com/article/1170337-overview. Last accessed 7th March 
2011. 
Rang HP, Dale MM, Ritter JM, Flower RJ (2007). Pharmacology. 6th ed. 
Philadelphia: Churchill Livingstone Elsevier. p562-563.Richter RW, Portenoy R, 
Sharma U, LaMoreaux L, Bockbrader H, Knapp LE. (2005). Relief of painful diabetic 
peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. 
Journal of Pain. 6 (4), p253-260. 
Rogers LC, Alam U, Tesfaye S, Malik RA. (2004). Treatment of painful diabetic 
neuropathy: a review of the most efficacious pharmacological treatments. Practical 
Diabetes International. 21 (8), p301-305. 
 
Ryle C, Donaghy M. (1995). Non-enzymatic glycation of peripheral nerve proteins in 
human diabetics. Journal of the Neurological Sciences. 129 (1), p62-8. 
The Plymouth Student Scientist, 2012, 5, (1), 61-78 
 
[78] 
 
 
Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. (2010). Evaluation of the safety 
and efficacy of pregabalin in older patients with neuropathic pain: results from a 
pooled analysis of 11 clinical studies. BMC Family Practice. 11, p85. 
 
Sharma U, Iacobellis D, Glessner C, Moore J, Young JP, LaMoreaux L, Poole RM. 
(2000). Pregabalin effectively relieves pain in two studies of patients with painful 
diabetic peripheral neuropathy. Presented at the Meeting of the American Pain 
Society.  
Tavakoli M, Mojaddidi M, Fadavi H, Malik RA. (2008). Pathophysiology and 
treatment of painful diabetic neuropathy. Current Pain and Headache Reports. 12 (3), 
p192-197. 
 
Walker R, Rodgers J (2004). Diabetes- A practical guide to managing your health. 
London: Dorling Kindersley Ltd. p23. 
 
Uthman BM, Bazil CW, Beydoun A, Schulze-Bonhage A, Benabou R, Whalen E, 
Emir B, Griesling T, Leon T. (2010). Long-term add-on pregabalin treatment in 
patients with partial-onset epilepsy: pooled analysis of open-label clinical 
trials. Epilepsia. 51 (6), p968-78. 
